Published in BMJ on January 26, 2006
Weight Based Enoxaparin in Trauma Patients (WeBET) | NCT01916707
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients | NCT00531843
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Thromboprophylaxis for adults in hospital. BMJ (2007) 3.74
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation (2009) 1.66
Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med (2012) 1.60
[Austrian Guidelines for Prophylaxis of Venous Thromboembolism]. Wien Klin Wochenschr (2007) 1.51
Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. Circulation (2014) 1.44
Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol (2014) 1.39
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Acute infections and venous thromboembolism. J Intern Med (2011) 1.30
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis (2009) 1.18
New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.11
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis (2012) 1.06
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci (2012) 0.98
Cancer-associated thrombosis: prevention and treatment. Curr Oncol (2008) 0.95
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep (2013) 0.95
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: results from the Indian subset data. Indian J Med Res (2012) 0.91
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol (2014) 0.88
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag (2006) 0.87
The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol (2010) 0.87
Primary prevention of venous thromboembolism in medical and surgical oncology patients. Br J Cancer (2010) 0.86
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis (2011) 0.86
Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag (2007) 0.86
Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol (2009) 0.85
Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Relat Outcome Meas (2011) 0.85
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol (2014) 0.83
Diet as prophylaxis and treatment for venous thromboembolism? Theor Biol Med Model (2010) 0.83
Incidence of Deep Vein Thrombosis in Hospitalized Chinese Medical Patients and the Impact of DVT Prophylaxis. Thrombosis (2011) 0.83
Prevention of venous thromboembolism in medical patients and outpatients. Nat Rev Cardiol (2009) 0.82
Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer (2008) 0.82
Thrombo-prophylaxis in acutely ill medical and critically ill patients. Indian J Crit Care Med (2014) 0.81
Cancer-associated thrombosis. Open Cardiovasc Med J (2010) 0.80
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J (2011) 0.80
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res (2014) 0.80
Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve. Ann Thorac Med (2010) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Cancer and coagulation. Am J Hematol (2012) 0.80
Occurrence of Deep Vein Thrombosis among Hospitalized Non-Surgical Japanese Patients. Ann Vasc Dis (2015) 0.80
Prevention and treatment of venous thromboembolism in patients with cancer. Can Pharm J (Ott) (2012) 0.79
Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol (2012) 0.79
Venous Thromboembolism-Incidence of Deep Venous Thrombosis and Pulmonary Embolism in Patients with Head and Neck Cancer: A Tertiary Care Experience in Pakistan. Int Arch Otorhinolaryngol (2015) 0.79
Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol (2015) 0.79
The effect of a provider-enhanced clinical decision support tool for guiding venous thromboembolism pharmacoprophylaxis in low-risk patients. Hosp Pract (1995) (2012) 0.78
Primary prevention of venous thromboembolism in elderly medical patients. Clin Interv Aging (2008) 0.78
Venous thromboembolic events in hospitalised medical patients. Thromb Haemost (2009) 0.78
Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. Thrombosis (2013) 0.78
Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. World J Gastrointest Oncol (2016) 0.77
Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes. Thrombosis (2011) 0.77
Prevention of venous thromboembolism in medically ill patients: a clinical update. Postgrad Med J (2006) 0.77
Adherence to local guidelines for venous thromboprophylaxis: a cross-sectional study of medical inpatients in Argentina. Thromb J (2011) 0.77
Prevention and treatment of venous thromboembolism in the elderly patient. Clin Interv Aging (2007) 0.77
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer (2011) 0.77
An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients. Thromb J (2006) 0.76
Linking joint commission inpatient core measures and national patient safety goals with evidence. Proc (Bayl Univ Med Cent) (2009) 0.76
Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux. Drug Des Devel Ther (2013) 0.75
A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. Thromb J (2015) 0.75
Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients? Nat Clin Pract Cardiovasc Med (2006) 0.75
Adherence to Venous Thromboprophylaxis Guidelines for Medical and Surgical Inpatients of Teaching Hospitals, Shiraz-Iran. Tanaffos (2015) 0.75
Prevention and treatment of venous thromboembolism in patients with cancer. Ther Adv Hematol (2012) 0.75
Preventing venous thromboembolism in cancer patients: can we do better? J Oncol Pract (2009) 0.75
A cohort study to analyze the risk of venous thromboembolism mortality in patients admitted to the general medicine department, tan tock seng hospital, singapore. Int J Angiol (2011) 0.75
Venous thromboembolism prophylaxis in hospitalized elderly patients: Time to consider a 'MUST' strategy. J Geriatr Cardiol (2011) 0.75
Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. Br J Clin Pharmacol (2012) 0.75
Thromboprophylaxis for adults in hospital: A mess for medical patients. BMJ (2007) 0.75
The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. Clinicoecon Outcomes Res (2012) 0.75
Inflammatory bowel disease and thrombosis. Turk J Haematol (2012) 0.75
Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study. J Korean Med Sci (2013) 0.75
Role of factor xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol (2011) 0.75
Venous thromboembolism risk assessment in hospitalised patients: a new proposal. Clinics (Sao Paulo) (2013) 0.75
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vasc Health Risk Manag (2006) 0.75
Effect of near-universal hospitalization-based prophylaxis on annual number of venous thromboembolism events in the US. Blood (2017) 0.75
[Thrombosis prophylaxis in geriatric patients]. Z Gerontol Geriatr (2012) 0.75
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med (1991) 7.62
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med (1999) 6.88
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Prevention of venous thromboembolism. Chest (2001) 5.59
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Deep-vein thrombosis. N Engl J Med (1994) 4.18
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med (2002) 3.96
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med (1989) 3.44
Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ (1991) 3.14
Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica (2002) 2.43
The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med (1994) 1.96
Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost (2000) 1.56
Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol (1997) 1.24
The changing pattern of venous thromboembolic disease. Haemostasis (1997) 1.23
Thromboprophylaxis in acute medical patients: need for an implementation strategy. Haematologica (2002) 0.97
Venous thromboembolic disease management of the nonsurgical moderate- and high-risk patient. Semin Hematol (2000) 0.94
Venous thromboembolic risk and prevention in acute medical illness. Int J Clin Pract (2003) 0.92
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med (2006) 6.62
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med (2010) 5.79
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med (2003) 5.02
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med (2002) 3.96
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95
Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr (2010) 2.91
Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens (2004) 2.71
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38
Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med (2004) 2.34
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med (2003) 2.22
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Safely ruling out deep venous thrombosis in primary care. Ann Intern Med (2009) 2.16
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
The association of direct thrombin inhibitor anticoagulants with cardiac thromboses. Chest (2015) 1.97
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84
Single-detector helical computed tomography as the primary diagnostic test in suspected pulmonary embolism: a multicenter clinical management study of 510 patients. Ann Intern Med (2003) 1.83
A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg (2002) 1.79
Prevention of venous thromboembolism. Chest (2005) 1.76
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67
Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens (2007) 1.66
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood (2011) 1.63
Perioperative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalization. Anesth Analg (2005) 1.60
The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 1.59
Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood (2002) 1.59
Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg (2010) 1.56
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev (2014) 1.52
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation (2010) 1.50
Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality. Intensive Care Med (2010) 1.50
Does fast-track treatment lead to a decrease of intensive care unit and hospital length of stay in coronary artery bypass patients? A meta-regression of randomized clinical trials. Crit Care Med (2006) 1.49
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res (2006) 1.48
Endoscopic ultrasound, positron emission tomography, and computerized tomography for lung cancer. Am J Respir Crit Care Med (2003) 1.48
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost (2010) 1.47
Low-dose heparin for severe sepsis. N Engl J Med (2002) 1.47
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46
Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace (2011) 1.45